June 25, 2019

ECH Announces Intention To Demerge Group of Companies

Independent Management and new corporate advisers will reinforce reputation at the forefront of the global cannabis industry.

ECH Media & Data and ECH Medical will pursue two very distinct growth strategies.

ECH (European Cannabis Holdings), the London based group of companies with a fundamental anchor in the global cannabis market, intends to demerge its operating companies and roll out two separate holding companies with a new management team and stand-alone growth strategy for each. 

Jeremy Edelman, Chairman, commented: “Our investment and incubation model has proved to be highly successful over the last 18 months. We put this down to a genuine understanding of cannabis and emerging markets, clarity of vision, strong strategic execution and an exceptionally talented team. This industry is now maturing and opening up at pace, so we are proud to announce this demerger which ensures independence and integrity across two distinctly different propositions.”

The company has engaged a new advisory team of Strand Hanson, Hill Dickinson and PKF to support and advise on the demerger and associated future transactions.


This new company will focus on delivering the industry’s only truly global offering across data, intelligence, consultancy and networking.

The following brands will form the key pillars of growth:

The company will be headquartered in London, UK, with the tech & data team in Dublin, Ireland and the consultancy & regulatory affairs team in Barcelona, Spain. 

Leadership will consist of Jeremy Edelman (Chairman), Stephen Murphy (CEO) and Daragh Anglim (MD, Prohibition Partners). Cannabis Europa and European Cannabis Week are joint ventures. 


A new medical holding company will take a comprehensive approach to improving access to medical cannabis for eligible patients around Europe by providing key infrastructure and educational services. 

It will include the following subsidiaries:

Dean Friday, previously ECH’s CFO, will take the reigns as CEO and will be joined on the leadership team by Prof. Mike Barnes (Chairman), Hannah Simon (COO), Jonathan Nadler (MD, Academy), Robert Whitehouse (MD, Astral) and Richard North (MD, Clinics). New Country Managers are being recruited at present for key European markets. 

Hannah Deacon, the tireless campaigner for UK access to medical cannabis for her young son Alfie Dingley and other children, will be Patient Advocacy Specialist.

The wider medical and scientific team includes Dr David Mc Dowell, Dr Elizabeth Iveson, Dr Dani Gordon, and Dr Leon Barron as well as a number of highly respected specialist physicians in the UK and general practitioners across Europe.

Back to all News Articles